NIH launches HIV prevention trial of long-acting injectable medication in women

(NIH/National Institute of Allergy and Infectious Diseases) The first large-scale clinical trial of a long-acting injectable medication for HIV prevention in sexually active women has begun. The study in southern and eastern Africa will examine whether a long-acting form of the investigational anti-HIV drug cabotegravir injected once every eight weeks can safely protect women at risk for HIV infection. NIH is sponsoring the trial, and the NIH-funded HIV Prevention Trials Network (HPTN) is conduc...